Trial Profile

A Phase I/II Dose Escalation, Tolerability, Safety, Pharmacokinetics and Multiple Cohort Expansion Study of ZGGS18 in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Dec 2024 Planned primary completion date changed from 1 Nov 2024 to 1 Nov 2025.
04 Jun 2024 Results (at the data cut-off 4 Jan 2024, n=21 patients) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
24 May 2024 According to a Zelgen Pharmaceuticals media release, as of April 23, 2024, a total of 21 subjects were enrolled; 14 of them were male and 7 were female; 16 of them had an ECOG score of 1 and 5 had an ECOG score of 0; all subjects had received at least first-line treatment before.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com